# Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

Study · id `cardio:ct-nct01624142` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01624142](<https://clinicaltrials.gov/study/NCT01624142>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01624142

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT01624142. Allocation not applicable; no masking; primary purpose treatment. Start 2012-06-01 (actual); primary completion 2018-05-11 (actual). Results posted on 2019-01-28.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT01624142, source copy `cardio:ctgov-nct01624142-2024-05-28`, retrieved 2026-10-31)
- Started: 2012-06-01 (actual) (ClinicalTrials.gov record NCT01624142, source copy `cardio:ctgov-nct01624142-2024-05-28`, retrieved 2026-10-31)
- Primary completion: 2018-05-11 (actual) (ClinicalTrials.gov record NCT01624142, source copy `cardio:ctgov-nct01624142-2024-05-28`, retrieved 2026-10-31)
- Completion: 2018-05-11 (actual) (ClinicalTrials.gov record NCT01624142, source copy `cardio:ctgov-nct01624142-2024-05-28`, retrieved 2026-10-31)
- Results first posted: 2019-01-28 (ClinicalTrials.gov record NCT01624142, source copy `cardio:ctgov-nct01624142-2024-05-28`, retrieved 2026-10-31)
- Countries: United States; Australia; Belgium; Brazil; Canada; Czechia; France; Greece; Hong Kong SAR China; Israel; Italy; Japan; Lebanon; Netherlands; New Zealand; South Africa; Spain; United Kingdom (ClinicalTrials.gov record NCT01624142, source copy `cardio:ctgov-nct01624142-2024-05-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01624142-2024-05-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
- Acronym: TAUSSIG
- Condition: Severe Familial Hypercholesterolemia
- Intervention (Biological): Evolocumab
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 96ced22e9437e2551c3d392c02a38ec928061259f08c20c0815c6c3315884994
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
